Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy - PubMed (original) (raw)

Review

Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy

Wentao Xia et al. Int J Mol Sci. 2021.

Abstract

Cancer is one of the primary causes of worldwide human deaths. Most cancer patients receive chemotherapy and radiotherapy, but these treatments are usually only partially efficacious and lead to a variety of serious side effects. Therefore, it is necessary to develop new therapeutic strategies. The emergence of nanotechnology has had a profound impact on general clinical treatment. The application of nanotechnology has facilitated the development of nano-drug delivery systems (NDDSs) that are highly tumor selective and allow for the slow release of active anticancer drugs. In recent years, vehicles such as liposomes, dendrimers and polymer nanomaterials have been considered promising carriers for tumor-specific drug delivery, reducing toxicity and improving biocompatibility. Among them, polymer nanoparticles (NPs) are one of the most innovative methods of non-invasive drug delivery. Here, we review the application of polymer NPs in drug delivery, gene therapy, and early diagnostics for cancer therapy.

Keywords: cancer therapy; drug delivery; polymer nanocarriers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Figure 1

The different types of polymer nanocarriers-based drug delivery for cancer therapeutics [136,137].

Figure 2

Figure 2

The self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy Reproduced from Song et al. [111].

Similar articles

Cited by

References

    1. Reyes-Farias M., Carrasco-Pozo C. The anti-cancer effect of quercetin: Molecular implications in cancer metabolism. Int. J. Mol. Sci. 2019;20:3177. doi: 10.3390/ijms20133177. - DOI - PMC - PubMed
    1. Cortes J., Perez-García J.M., Llombart-Cussac A., Curigliano G., El Saghir N.S., Cardoso F., Barrios C.H., Wagle S., Roman J., Harbeck N. Enhancing global access to cancer medicines. CA Cancer J. Clin. 2020;70:105–124. doi: 10.3322/caac.21597. - DOI - PubMed
    1. Li Y., Liu W., Zhao L., Güngör C., Xu Y., Song X., Wang D., Zhou Z., Zhou Y., Li C. Nomograms predicting overall survival and cancer-specific survival for synchronous colorectal liver-limited metastasis. J. Cancer Res. Clin. Oncol. 2020;11:6213. - PMC - PubMed
    1. Wang N., Mengersen K., Tong S., Kimlin M., Zhou M., Hu W. Global, regional, and national burden of lung cancer and its attributable risk factors, 1990 to 2017. Cancer. 2020;126:4220–4234. doi: 10.1002/cncr.33078. - DOI - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources